DCL: Board approves to invest in Benovas

The Board of Directors of Cuu Long Pharmaceutical Joint Stock Company (HOSE: DCL) unanimously approved to invest VND55 billion, equivalent to 55%, in the establishment of Benovas Cancer Drug Joint Stock Company (*). The capital contribution will start from March 15, 2017.

The Board appointed Mr. Nguyen Van Sang as DCL’s representative to manage the stake of DCL at Benovas Cancer Drug Joint Stock Company.

(*) temporary translation 

HOSE

>   HPG: Hoa Phat Group adjusts revenue & profit targets for 2017 (02/03/2017)

>   TCL: Resolution on dividend payment & AGM (04/07/2017)

>   STB: Notice of the holding of Annual General Meeting (03/03/2017)

>   PAN: Record date for Annual General Meeting 2017 (03/03/2017)

>   NTL: Notice of the holding of Annual General Meeting 2017 (03/03/2017)

>   DHM: Notice of time & venue for 2017 AGM (09/03/2017)

>   PDR: Board resolution on the contents of AGM (09/03/2017)

>   DTA: Resolution on the company’s business result in 2016 & plans for 2017 (08/03/2017)

>   MSN: Record date of the holding of the 2017 AGM (08/03/2017)

>   VNM: Approved to delay the disclosure of financial statements (03/03/2017)